Sirona Biochem Corp. · OTC:SRBCF
Sirona Biochem — Innocos World Beauty Innovation Summit 2016
22 slides from Sirona Biochem's conference presentation, June 2016
Slide 1: Innocos World Beauty Innovation Summit
Innocos World Beauty Innovation Summit Vienna, Austria June 9-10, 2016 TM TSX-V: SBM
Slide 2: Introduction and History
Introduction and History Sirona Biochem (Parent Company) TFChem (Wholly Owned Subsidiary) Vancouver, BC, Canada Cosmetic Valley, France • Sirona Biochem was founded in 2009 • TFChem was acquired in 2011 TSX-V: SBM
Slide 3: Sirona's Fluorination Chemistry Technology
Sirona’s Fluorination Chemistry Technology The Solution to Unstable Carbohydrate Molecules Carbohydrate molecules are unstable by nature Our technology stabilizes carbohydrate molecules Resulting in improved bioavailability and selectivity that translates into better safety and efficacy TSX-V: SBM
Slide 4: Current Collaborations & Pipeline
Current Collaborations & Pipeline Cosmetic Products Therapeutic Area Compound Partnering Status Melasma/Hyperpigmentation/ SBM-TFC-849 Valeant Skin lightening Melasma/Hyperpigmentation/ SBM-TFC-1067 In partnering discussions Skin lightening Cell Preservation SBM-TFC-837 Undergoing testing Pharmaceut
Slide 5: Business Development Strategy
Business Development Strategy • License 1067 to a major industry partner with a commercial and R&D Infrastructure in Japan, Asia-Pacific, Europe and North America TSX-V: SBM
Slide 6: Leading Cosmetic and Pharmaceutical Companies
Leading Cosmetic and Pharmaceutical Companies TSX-V: SBM
Slide 7: Large unmet needs for Asian consumers
Large unmet needs for Asian consumers 25.0 20.0 $ billions 15.0 10.0 5.0 0.0 2015 2016 2017 2018 Japan 12.8 13.2 13.7 14.1 Asia-Pacific 4.1 4.5 4.8 5.2 US, EU, ROW 0.4 0.4 0.4 0.5 TSX-V: SBM
Slide 8: The Problem
The Problem Hydroquinone, deoxyarbutin and arbutin are commonly used skin-lightening agents that have safety risks associated with their use • Deoxyarbutin and arbutin break down into hydroquinone • Hydroquinone is banned in the EU and restricted in USA • The problem is to develop a safe and effecti
Slide 9: Sirona Biochem's Solution
Sirona Biochem ’s Solution SBM-TFC- Superior safety and 8 times the 1067 efficacy of deoxyarbutin. • We have developed a safe and effective skin lightener in an area with significant unmet need TSX-V: SBM
Slide 10: Safety of SBM-TFC-1067
Safety of SBM-TFC-1067 In vitro stability: percentage of hydroquinone released 140 128.6 120 Hydroquinone Released (%) Water RT 14 days Bis Tris buffer RT 14 days 100 88.8 PBS RT 14 days Ringer solution at pH 6.8 at RT 14 days 80 Ringer solution at pH 5.5 at 70°C 24H Ringer solution at pH 8.5 at 70°
Slide 11: Efficacy of SBM-TFC-1067
Efficacy of SBM-TFC-1067 Inhibition of Human Tyrosinase (300U/ml) 0.4 0.272 mM 0.3 IC50 (mM) 0.2 0.1 0.035 mM 0 SBM-TFC-1067 Deoxyarbutin SBM-TFC-1067 has 8 times the efficacy of deoxyarbutin TSX-V: SBM
Slide 12: Safety and Efficacy Summary
Safety and Efficacy Summary Safety Efficacy • Superior safety profile over deoxyarbutin • 8 times the efficacy of with zero hydroquinone released deoxyarbutin • High flux capacity to the site of • No genotoxicity (0-0.25%) action in the epidermis • Very minor ocular irritation at 0.14% • Antioxidant
Slide 13: New Study Design
New Study Design • Purpose: To evaluate the skin lightening effect of SBM-TFC-1067 in an in vitro human skin model • Endpoints: o Skin pigmentation o Melanin quantification o Histology o Morphological assessment TSX-V: SBM
Slide 14: Measurement of Skin Pigmentation Results
Measurement of Skin Pigmentation Results Average L(*D65) Measurements Day 0 -14 Day 0 Day 7 Day 11 Day 14 AVG STD AVG STD AVG STD AVG STD DEV DEV DEV DEV Vehicle Control (topical) 61.62 1.04 45.76 1.65 36.70 2.02 32.37 2.17 0.1% SBM-TFC-1067 (topical) 60.82 0.37 47.72 1.21 42.85 1.00 40.32 1.79 0.05
Slide 15: Melanin Quantification
Melanin Quantification Quantification of melanin (in µg) at Day 14 Tissue 1 Tissue 2 Tissue 3 AVG STD Difference DEV (TA-Control) Vehicle Control (topical) 39.57 40.80 44.12 41.50 2.36 0.1% SBM-TFC-1067 (topical) 17.50 22.76 27.13 22.46 4.82 -19.03 0.05% SBM-TFC-1067 (topical) 30.29 34.84 31.69 32.2
Slide 16: Tissue Pigmentation
Tissue Pigmentation On day 14, the surface of n=4 tissues from each treatment group were digitally imaged to capture the level of surface pigmentation. TSX-V: SBM
Slide 17: Melanocyte Morphology
Melanocyte Morphology Tissues treated with Vehicle Tissues treated topically with Tissues treated topically with Tissues treated topically with Control 0.1% SBM-TFC-1067 0.05% SBM-TFC-1067 0.01% SBM-TFC-1067 TSX-V: SBM
Slide 18: Histological Analysis
Histological Analysis A. Tissues treated topically with vehicle control B. Tissues treated topically with 0.1% SBM-TFC- photographed on day 14 1067 photographed on day 14 C. Tissues treated topically with 0.05% SBM-TFC- D. Tissues treated topically with 0.01% SBM-TFC- 1067 photographed on day 14 106
Slide 19: Skin Lightening Efficacy of SBM-TFC-1067
Skin Lightening Efficacy of SBM-TFC-1067 Surface Reflectance as a Measure of Pigmentation (L*D65) 70 65 60 55 p=0.017 50 L*D65 * p=0.033 45 * 40 35 30 25 Day 0 Day 7 Day 11 Day 14 Vehicle Control SBM-TFC-1067 (0.05% topical) TSX-V: SBM * statistical significance (p< 0.05)
Slide 20: Skin Lightening Efficacy of SBM-TFC-1067
Skin Lightening Efficacy of SBM-TFC-1067 Quantification of Melanin at Day 14 50 p=0.009 * 45 Melanin Quantity (µg) 40 ∆=-9.22µg or 22% reduction in melanin after 14 days 35 30 25 Day 14 Vehicle Control SBM-TFC-1067 (0.05% topical) TSX-V: SBM * statistical significance (p< 0.05)
Slide 21: Results and Conclusions
Results and Conclusions • At a concentration of 0.05%, SBM-TFC-1067 was shown to have a significant skin lightening effect and to significantly reduce melanin in an in vitro human skin model without any evidence of cytotoxicity • With these promising results, SBM-TFC-1067 would be very useful as a c
Slide 22: Summary
Summary • Sirona Biochem is a discovery and development stage biotechnology company that is the leader in commercializing carbohydrate chemistry • There is an opportunity to license SBM- TFC-1067 and generate significant revenues in a $20 billion market with a safe and effective product TSX-V: SBM
Sirona Biochem — Innocos World Beauty Innovation Summit 2016 on 6ix